



#### Potential Commercial Applications

- Therapeutic potential for treating general and drug-resistant bacterial infections in clinical and veterinary populations.

- Antiseptics in hospital settings.

#### Competitive Advantages

- Effective for commonly occurring drug-resistant infections MRSA and VRE.
- Broad spectrum of efficacy because mechanism of action is against the bacterial protein FtsZ, which has similar structure in all bacteria.
- Potential for additive efficacy when combined with other antibiotics due to distinct mechanism of action.
- Other drugs with similar structure and antibacterial properties can be synthesized using the chemical structure template shown above.

#### Development Stage

- Early-stage.
- In vitro data available.

*Inventors:* Carole A Bewley, et al. (NIDDK).

*Publication:* Plaza A, et al.

Chrysohaentins A–H, antibacterial bisdiarylbutene macrocycles that inhibit the bacterial cell division protein FtsZ. *J Am Chem Soc.* 2010 Jul 7;132(26):9069–9077. [PMID 20536175].

*Intellectual Property:* HHS Reference No. E–116–2010/0—PCT Application No. PCT/US2011/026200 filed 25 Feb 2011, which published as WO 2011/106630 on 01 Sep 2011.

*Licensing Contact:* John Stansberry, Ph.D.; 301–435–5236; [stansbej@mail.nih.gov](mailto:stansbej@mail.nih.gov).

*Collaborative Research Opportunity:* The National Institute of Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic Chemistry, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the chrysohaentins antibiotics. Please contact Marguerite J. Miller at 301–451–3636 or [miller marg@nidk.nih.gov](mailto:miller marg@nidk.nih.gov) for more information.

Dated: February 21, 2012.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2012–4376 Filed 2–24–12; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of General Medical Sciences; Notice of Closed Meeting Pursuant to Section 10(d) of the Federal Advisory Committee Act, as Amended (5 U.S.C. App.), Notice Is Hereby Given of the Following Meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of General Medical Sciences Special Emphasis Panel Review of Minority Biomedical Research Support Genetics Applications.

*Date:* March 19–20, 2012.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency—Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Saraswathy Seetharam, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3An12C, Bethesda, MD 20892, 301–594–2763, [seetharams@nigms.nih.gov](mailto:seetharams@nigms.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: February 21, 2012.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2012–4526 Filed 2–24–12; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Deafness and Other Communication Disorders Special Emphasis Panel P30 Review

*Date:* March 28, 2012.

*Time:* 12:30 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6120 Executive Blvd., Rockville, MD 20852 (Telephone Conference Call).

*Contact Person:* Christine A. Livingston, Ph.D. Scientific Review Officer, Division of Extramural Activities, National Institutes of Health/NIDCD, 6120 Executive Blvd.—MSC 7180, Bethesda, MD 20892, (301) 496–8683, [livingsc@mail.nih.gov](mailto:livingsc@mail.nih.gov).

Information is also available on the Institute's/Center's home page: <http://www.nidcd.nih.gov/about/groups/sep/>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.173, Biological Research Related to Deafness and Communicative Disorders, National Institutes of Health, HHS)

Dated: February 21, 2012.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2012–4535 Filed 2–24–12; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as